Alpha Teknova Reports 7% Revenue Growth to $10.3 Million for Q2 2025

Alpha Teknova, Inc. reported a revenue of $10.3 million for the three months ended June 30, 2025, marking a 7% increase from $9.6 million in the same period last year. For the six months ending June 30, 2025, the company generated $20.1 million in revenue, up from $18.9 million in the prior year, reflecting a growth of 6.2%. The increase in revenue was primarily driven by a rise in customer counts, particularly in the Clinical Solutions segment, which saw a 31.6% increase in revenue to $2.1 million. Gross profit for the second quarter was $4.0 million, yielding a gross margin of 38.7%, compared to 29.2% in the previous year, attributed to improved manufacturing efficiencies.

Operating expenses decreased to $7.4 million for the second quarter of 2025, down from $7.9 million in the same quarter of 2024. This reduction was largely due to a decrease in general and administrative expenses, which fell by 10.1% to $4.9 million. The company reported a loss from operations of $3.4 million for the second quarter, an improvement from a loss of $5.1 million in the same period last year. For the first half of 2025, the net loss was $8.2 million, significantly reduced from $13.5 million in the prior year, indicating a 39% improvement.

In terms of operational developments, Alpha Teknova has focused on enhancing its manufacturing capabilities and expanding its workforce. The company has invested in new facilities to improve operational efficiency and capacity. As of June 30, 2025, the company had approximately 3,000 customers, with a notable increase in customer engagement metrics. The company also reported a slight increase in inventory levels, which rose to $7.6 million from $6.8 million at the end of 2024, reflecting its strategy to meet growing demand.

The company’s balance sheet as of June 30, 2025, showed total assets of $110.5 million, down from $118.8 million at the end of 2024, primarily due to a decrease in short-term investments. Total liabilities decreased to $34.4 million from $36.4 million, driven by a reduction in current liabilities. Alpha Teknova's cash and cash equivalents stood at $3.3 million, down from $3.7 million at the end of 2024, indicating a need for careful cash management moving forward.

Looking ahead, Alpha Teknova anticipates continued revenue growth as it expands its product offerings and customer base. The company is closely monitoring economic conditions, including inflation and interest rates, which could impact customer purchasing behavior. Management expects to increase operational expenses in the future to support hiring and infrastructure investments, aiming to enhance its market position in the life sciences sector.